Xuanzhu Biopharm Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
344
- Stock Symbol
-
02575
- Investments
-
2
- Share Price
-
$1.05
- (As of Friday Closing)
Xuanzhu Biopharm General Information
Description
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
Contact Information
Website
www.xuanzhubio.comCorporate Office
- 9th Floor, North Tower of CP Center
- No.20 Jin He East Avenue,Chaoyang District
- Beijing
- China
Corporate Office
- 9th Floor, North Tower of CP Center
- No.20 Jin He East Avenue,Chaoyang District
- Beijing
- China
Xuanzhu Biopharm Stock Performance
As of 13-Nov-2026, Xuanzhu Biopharm’s stock price is $1.05. Its current market cap is $546M with 518M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.05 | $1.13 | $0.96 - $12.45 | $546M | 518M | 2.19M | -$0.07 |
Xuanzhu Biopharm Financials Summary
As of 30-Jun-2026, Xuanzhu Biopharm has a trailing 12-month revenue of $14.8M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 788,121 | 4,668,455 | ||
| Revenue | 14,766 | 7,199 | 4,194 | 4 |
| EBITDA | (26,187) | (30,631) | (72,850) | (37,823) |
| Net Income | (30,003) | (34,140) | (77,546) | (42,483) |
| Total Assets | 227,895 | 234,446 | 163,918 | 186,357 |
| Total Debt | 32 | 92 | 203 | 2,407 |
Xuanzhu Biopharm Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Xuanzhu Biopharm Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Xuanzhu Biopharm Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Xuanzhu Biopharm Patents
Xuanzhu Biopharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025140560-A1 | Pharmaceutical composition of anaplastic lymphoma kinase inhibitor and preparation method therefor | Inactive | 28-Dec-2023 | ||
| WO-2024220556-A2 | Heterocyclic sumo1 small molecule degraders and use thereof | Inactive | 20-Apr-2023 | ||
| WO-2024220556-A3 | Heterocyclic sumo1 small molecule degraders and use thereof | Inactive | 20-Apr-2023 | ||
| WO-2024104448-A1 | Pharmaceutical composition of cdks inhibitor and preparation method therefor | Inactive | 18-Nov-2022 | ||
| EP-4613752-A1 | Polycyclic poly(adp-ribose) polymerase selective inhibitor | Pending | 02-Nov-2022 | A61P35/00 |
Xuanzhu Biopharm Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Xuanzhu Biopharm Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Xuanzhu Biopharm Investments & Acquisitions (2)
Xuanzhu Biopharm’s most recent deal was a Later Stage VC with Contraline for . The deal was made on 17-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Contraline | 17-Jun-2026 | Later Stage VC | Drug Discovery | ||
| Beijing Combio Pharmaceutical | 02-Jun-2021 | Merger/Acquisition | Drug Discovery |
Xuanzhu Biopharm ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Xuanzhu Biopharm FAQs
-
When was Xuanzhu Biopharm founded?
Xuanzhu Biopharm was founded in 2002.
-
Where is Xuanzhu Biopharm headquartered?
Xuanzhu Biopharm is headquartered in Beijing, China.
-
What is the size of Xuanzhu Biopharm?
Xuanzhu Biopharm has 344 total employees.
-
What industry is Xuanzhu Biopharm in?
Xuanzhu Biopharm’s primary industry is Drug Discovery.
-
Is Xuanzhu Biopharm a private or public company?
Xuanzhu Biopharm is a Public company.
-
What is Xuanzhu Biopharm’s stock symbol?
The ticker symbol for Xuanzhu Biopharm is 02575.
-
What is the current stock price of Xuanzhu Biopharm?
As of 13-Nov-2026 the stock price of Xuanzhu Biopharm is $1.05.
-
What is the current market cap of Xuanzhu Biopharm?
The current market capitalization of Xuanzhu Biopharm is $546M.
-
What is Xuanzhu Biopharm’s current revenue?
The trailing twelve month revenue for Xuanzhu Biopharm is $14.8M.
-
What is Xuanzhu Biopharm’s annual earnings per share (EPS)?
Xuanzhu Biopharm’s EPS for 12 months was -$0.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
